Patients with ≤2 aneuploidies (n = 233, 11%), enriched for “MDS-related”16,17 cytogenetic abnormalities clustered with secondary AML type mutations (sAML)16 such as SRSF2, SF3B1, U2AF1, ZRSR2, ASXL1, EZH2, BCOR, or STAG2, as well as novelly described here, RUNX1, SETBP1, and MLLPTD mutations. This evidence concerns the gene SF3B1 and myelodysplastic syndrome.